THC Patches, Suppositories, and Topicals: Non-Inhalation Methods Explained

Product Types

70%

Transdermal patches deliver steady cannabinoid levels over 8 to 12 hours while suppositories may absorb up to 70 percent of THC, offering alternatives that bypass both the lungs and edible unpredictability.

Journal of Pharmaceutical Sciences, 2010

Journal of Pharmaceutical Sciences, 2010

View as image

Most cannabis conversations focus on two delivery methods: smoking it or eating it. But the pharmaceutical and cannabis industries have developed several alternative routes of administration that avoid the lungs entirely. Transdermal patches, topical creams, rectal suppositories, sublingual strips, and vaginal suppositories each deliver cannabinoids through different biological pathways, with different onset times, durations, and bioavailability profiles.

These methods are not mainstream recreational products. They are primarily relevant for medical users, people who want the therapeutic potential of cannabinoids without the respiratory risks of inhalation or the unpredictability of edibles. Understanding how each method works helps clarify which might be useful for specific situations and which claims are supported by evidence.

Transdermal Patches: Slow and Steady

Product Types

Non-Inhalation Cannabinoid Delivery Methods

Transdermal PatchPsychoactive

Through skin → bloodstream

Onset: 30 min – 2 hrs

Duration: 8–12 hrs

Bioavail: Variable (enhancer-dependent)

Liver bypass: Yes

Topical Cream/BalmNon-psychoactive

Skin surface only

Onset: 15–45 min

Duration: 2–4 hrs

Bioavail: Minimal systemic

Liver bypass: N/A (stays local)

Sublingual Strip/SprayPsychoactive

Under tongue → blood

Onset: 15–30 min

Duration: 2–6 hrs

Bioavail: Higher than oral

Liver bypass: Partial

SuppositoryPsychoactive

Rectal/vaginal → blood

Onset: 15–30 min

Duration: 4–8 hrs

Bioavail: 50–70% (estimated)

Liver bypass: Partial (rectal)

Best-studied product: Nabiximols (Sativex) — sublingual spray with 1:1 THC:CBD — approved in multiple countries for MS spasticity. All others have limited clinical trial data.

J Pharmaceutical Sciences (2004, 2010)Non-Inhalation Cannabinoid Delivery Methods

Transdermal drug delivery is well-established in pharmaceutical medicine. Nicotine patches, fentanyl patches, estrogen patches, and scopolamine patches all use the same basic principle: a drug reservoir is applied to the skin, and the active compound passes through the skin layers into the bloodstream at a controlled rate.

Cannabis transdermal patches work on the same principle. A patch containing THC, CBD, or a combination is applied to a venous area of the skin (typically the inner wrist, ankle, or upper arm). The cannabinoid crosses the stratum corneum (the outermost skin barrier), enters the epidermis and dermis, reaches the capillary network, and enters systemic circulation.

The key pharmacological advantage is bypassing first-pass metabolism. When you eat an edible, THC passes through the liver before reaching the brain, where it is converted to 11-hydroxy-THC, a more potent but also more unpredictable metabolite. Transdermal delivery sends THC directly into the blood, similar to inhalation, but at a slow, controlled rate rather than a rapid bolus.

Most cannabis patches are designed to deliver their payload over 8 to 12 hours. The onset is slow, typically 30 minutes to 2 hours, because the drug must cross multiple skin layers. The effect profile is a sustained plateau rather than a sharp peak and decline. This makes patches potentially useful for chronic conditions requiring consistent cannabinoid levels, such as ongoing pain management.

The challenges are real. Cannabinoids are highly lipophilic (fat-soluble), which means they do not easily penetrate the aqueous layers of the skin. Most transdermal cannabis products use permeation enhancers, chemical compounds that temporarily disrupt the skin barrier to improve drug transport. The effectiveness of these enhancers varies, and not all patches deliver cannabinoids as efficiently as their labels suggest.

A 2004 study by Stinchcomb and colleagues in the Journal of Pharmaceutical Sciences examined the transdermal delivery of delta-8-THC in human skin models and found that meaningful permeation was achievable with appropriate enhancers. A subsequent 2010 study by Valiveti and colleagues in Drug Development and Industrial Pharmacy confirmed that permeation enhancers significantly increased THC flux across human skin. These are in vitro studies, however, and clinical trials measuring blood levels and therapeutic outcomes in patients using commercially available patches are scarce.

The practical question for consumers is whether commercially available patches actually deliver the labeled dose at a therapeutically relevant rate. Without batch-specific pharmacokinetic data, this is difficult to verify. Patches from regulated markets with third-party testing offer more reliability than unregulated products.

Topical Creams and Balms: Localized Only

Topical cannabis products, creams, balms, salves, and lotions, are applied to the skin surface for localized relief. They are marketed primarily for joint pain, muscle soreness, skin inflammation, and localized nerve pain.

The critical distinction between topicals and transdermal patches is penetration depth. Standard topical formulations are designed to deliver cannabinoids into the skin but not through the skin into the bloodstream. The cannabinoids interact with CB1 and CB2 receptors in the skin, subcutaneous tissue, and local nerve endings, but systemic blood levels remain negligible.

This means standard topicals will not get you high, will not show up on a drug test, and will not produce whole-body effects. They are purely local-acting products.

The evidence for topical cannabinoid efficacy is a mix of reasonable pharmacology and limited clinical data. CB2 receptors are present in skin cells, and activation of these receptors has anti-inflammatory effects in preclinical models. A 2016 study by Hammell and colleagues in the European Journal of Pain found that topical CBD reduced joint swelling and pain behaviors in a rat model of arthritis. The inflammation markers decreased at the application site, suggesting local anti-inflammatory activity.

Human clinical data on topical cannabis products is sparse. Most evidence is anecdotal or from small, uncontrolled studies. The placebo response for topically applied pain products is notoriously high, making it difficult to separate genuine pharmacological effects from expectation effects without large, well-designed controlled trials.

One legitimate concern with topicals is formulation quality. The vehicle (the cream or oil base that carries the cannabinoid) affects how well the active compound penetrates the skin. A poorly formulated topical may deposit cannabinoids on the skin surface without meaningful penetration to the target tissue. There is no standardized testing for topical penetration efficiency in the commercial cannabis market.

Suppositories: High Bioavailability Claims, Limited Data

Cannabis suppositories, both rectal and vaginal, are perhaps the least discussed and most pharmacologically interesting delivery method. They are used primarily by medical patients seeking high bioavailability without inhalation, particularly patients with nausea, GI issues, or difficulty swallowing.

The pharmacological rationale is sound. The rectal mucosa has a rich vascular network, and drugs absorbed through the lower rectum can partially bypass first-pass liver metabolism (the superior rectal veins drain into the portal system, but the middle and inferior rectal veins drain directly into systemic circulation). This means that a portion of rectally administered THC enters the bloodstream without being converted to 11-hydroxy-THC in the liver.

Some proponents claim rectal bioavailability of THC as high as 50% to 70%, compared to approximately 6% to 15% for oral ingestion. A 1985 study by Mattes and colleagues in Pharmacology, Biochemistry and Behavior examined rectal administration of THC in a small group of subjects and found detectable plasma THC levels with different absorption kinetics than oral administration. However, the number of rigorous human studies on cannabis suppositories is very small, and the often-cited high bioavailability figures are extrapolated from general pharmaceutical principles rather than established by large clinical trials specific to cannabis.

Vaginal suppositories are marketed primarily for menstrual cramps, pelvic pain, and sexual discomfort. The vaginal mucosa also has significant vascularization, and local absorption can deliver cannabinoids to pelvic tissues. A small 2020 study by Sinclair and colleagues published in the Journal of Cannabis Research found that cannabis use was associated with improved sexual function in women, though this was a survey study, not a controlled trial of vaginal suppositories specifically.

The honest assessment is that the theoretical pharmacology of suppository delivery is promising, but the clinical evidence specific to cannabis suppositories is extremely limited. Most available data comes from anecdotal reports, very small studies, and extrapolation from general drug delivery science. If you are considering suppositories for a medical condition, discussing the limited evidence base with a knowledgeable healthcare provider is advisable.

Sublingual Strips and Sprays

Sublingual delivery involves placing a product under the tongue, where cannabinoids absorb through the thin mucous membrane directly into the blood supply. This route partially bypasses first-pass metabolism (though some swallowed product will undergo hepatic metabolism).

Sublingual strips are thin, dissolvable films infused with a measured dose of THC, CBD, or a combination. They dissolve in 1 to 3 minutes when placed under the tongue. Sublingual sprays, like nabiximols (Sativex), deliver a metered dose of cannabinoid solution to the sublingual or buccal (inner cheek) mucosa.

The onset time for sublingual delivery is typically 15 to 30 minutes, faster than edibles (30 minutes to 2 hours) but slower than inhalation (seconds to minutes). The duration is generally 4 to 6 hours. Dosing precision is good because each strip or spray actuation delivers a consistent amount.

Nabiximols is the best-studied sublingual cannabis product. It contains approximately equal parts THC and CBD and has been approved in multiple countries for multiple sclerosis spasticity. Clinical trials showed meaningful symptom reduction with a well-characterized pharmacokinetic profile. This provides the strongest evidence that sublingual cannabinoid delivery works in a clinically meaningful way.

For consumers, sublingual tinctures (liquid drops held under the tongue) operate on the same principle. The key is holding the product under the tongue long enough for mucosal absorption rather than swallowing it immediately, which converts it to a conventional oral dose with slower onset and lower bioavailability. For more on tinctures, see what is a tincture.

Who Benefits From Each Method

Each delivery method fills a different niche, and the best choice depends on the user's specific needs and circumstances.

Transdermal patches are best suited for people who need sustained, consistent cannabinoid delivery over many hours. This includes chronic pain patients, people managing persistent symptoms, and anyone who benefits from avoiding the peaks and valleys of other methods. They are also useful for people who cannot or prefer not to inhale and who find edible dosing unpredictable.

Topicals are best for localized pain, inflammation, or skin conditions where systemic effects are unnecessary and undesired. They carry no psychoactive effects and no drug test risk, making them the lowest-barrier cannabis product for people who want to try cannabinoids for a specific, localized issue.

Suppositories fill a niche for medical patients who cannot tolerate oral or inhaled delivery, such as those with severe nausea, oral mucositis from cancer treatment, or GI disorders that impair oral absorption. They may also be relevant for pelvic conditions where localized vaginal delivery is desired.

Sublingual products offer a middle ground: faster onset than edibles, more precise dosing than inhalation, no respiratory exposure, and partial bypass of first-pass metabolism. They are suitable for a wide range of users who want a predictable, smoke-free experience.

Comparison to Inhalation and Edibles

Understanding how these methods stack up against more common delivery routes provides useful context.

Onset speed: Inhalation is fastest (seconds). Sublingual is moderate (15-30 minutes). Patches and edibles are slowest (30 minutes to 2 hours).

Duration: Patches are longest (8-12 hours). Edibles are moderate to long (4-8 hours). Sublingual is moderate (4-6 hours). Inhalation is shortest (1-3 hours).

Bioavailability: Inhalation delivers approximately 30% of the cannabinoid content to the bloodstream. Sublingual delivers an estimated 20-35%. Oral (edible) delivery ranges from 6-15%. Transdermal and rectal delivery vary widely depending on formulation, but theoretical bioavailability is potentially high for well-formulated products.

Predictability: Sublingual strips and sprays offer the most consistent dosing. Patches offer consistent delivery rate but variable total absorption. Edibles are the most variable due to differences in digestion, stomach contents, and individual metabolism. Inhalation is moderately consistent but depends on inhalation technique.

Safety profile: Non-inhalation methods avoid all respiratory risks. Patches and topicals have minimal side effects. Edibles carry the highest overconsumption risk due to delayed onset. For a detailed comparison of how different routes change the THC experience, see sublingual vs oral vs inhaled THC.

The Bottom Line

Non-inhalation delivery methods expand the options for cannabis use beyond smoking, vaping, and eating. Each method operates through different pharmacological pathways, producing different effect profiles. Transdermal patches offer sustained delivery. Topicals provide localized relief. Suppositories deliver high bioavailability in specific medical contexts. Sublingual products balance speed and precision.

The evidence base varies significantly across these methods. Sublingual delivery (nabiximols) has the most robust clinical data. Topicals and patches have reasonable pharmacological support but limited human trials. Suppositories have the thinnest evidence despite promising theory.

For most consumers, the practical choice comes down to what you need: localized or systemic effects, fast or sustained onset, and whether avoiding inhalation is a priority. Knowing how each method works gives you the framework to match the delivery system to the goal.

The Bottom Line

Guide to non-inhalation cannabinoid delivery methods with pharmacokinetic profiles. Transdermal patches: drug reservoir on skin, cannabinoid crosses stratum corneum into capillaries, bypasses first-pass liver metabolism, delivers over 8-12 hours at controlled rate; 2004 Stinchcomb J Pharm Sci and 2010 Valiveti Drug Dev Ind Pharm confirmed meaningful permeation with enhancers (in vitro); challenge is THC's lipophilicity limiting aqueous skin layer penetration. Topicals (creams/balms): deliver cannabinoids INTO skin but not THROUGH to bloodstream; CB1/CB2 receptors in skin/subcutaneous tissue activated locally; no psychoactive effects, no drug test risk; 2016 Hammell Eur J Pain — topical CBD reduced joint swelling in rat arthritis model; human clinical data sparse, high placebo response. Suppositories (rectal/vaginal): rich vascular network, partial first-pass bypass via inferior/middle rectal veins; bioavailability claims of 50-70% based on pharmaceutical principles but very limited cannabis-specific human studies; 1985 Mattes Pharmacol Biochem Behav detected plasma THC from rectal administration. Sublingual strips/sprays: mucosal absorption, 15-30 min onset, partial first-pass bypass; nabiximols (Sativex) is best-studied sublingual cannabis product — approved in multiple countries, THC:CBD ~1:1, rigorous clinical trials. Comparison table: onset (inhaled seconds > sublingual 15-30min > edible/patch 30min-2h), duration (patch 8-12h > edible 4-8h > sublingual 4-6h > inhaled 1-3h), bioavailability (inhaled ~30%, sublingual ~20-35%, oral 6-15%, transdermal/rectal variable).

Frequently Asked Questions

Will a THC patch get you high?

Yes, if it is a transdermal patch designed to deliver THC into the bloodstream. Transdermal patches bypass first-pass liver metabolism and deliver delta-9-THC directly into systemic circulation at a slow, controlled rate over 8 to 12 hours. The psychoactive effect is typically milder and more sustained than inhalation — a long plateau rather than a sharp peak. The onset is slow (30 minutes to 2 hours), so you will not feel an immediate rush. Some patches contain only CBD and will not produce psychoactive effects. Check the cannabinoid content on the label to know what type of patch you are using.

Do cannabis topicals show up on drug tests?

Standard topical creams and balms that do not penetrate to the bloodstream should not produce detectable THC metabolites in standard drug tests. However, transdermal patches are different — they deliver cannabinoids into systemic circulation and will produce the same THC metabolites as any other consumption method. If you are subject to drug testing, standard topicals (creams, balms, salves) are generally safe, but transdermal patches should be treated with the same caution as edibles or inhalation. Always check whether the product is formulated for topical-only or transdermal delivery.

Do cannabis suppositories actually work?

The theoretical pharmacology is promising — the rectal and vaginal mucosa have rich vascular networks that can absorb drugs efficiently, and the lower rectum partially bypasses first-pass liver metabolism. Proponents cite bioavailability of 50 to 70 percent, but these figures are extrapolated from general pharmaceutical principles rather than established by large clinical trials specific to cannabis suppositories. A 1985 study detected plasma THC from rectal administration, confirming absorption does occur. However, the number of rigorous human studies is very small. If you are considering suppositories for a medical condition, the limited evidence base is worth discussing with a knowledgeable healthcare provider.

How long do THC patches last?

Most commercial cannabis transdermal patches are designed to deliver their payload over 8 to 12 hours. Onset is slow — typically 30 minutes to 2 hours as the cannabinoid crosses multiple skin layers. The effect profile is a sustained plateau rather than the sharp peak and decline of inhalation. Some patches are designed to be worn for up to 72 hours with a slower release rate. The actual duration and effectiveness depend on the patch formulation, the permeation enhancers used, the application site (venous areas like inner wrist or ankle work best), and individual skin characteristics. Removing the patch stops further absorption, but cannabinoids already in the bloodstream will continue to produce effects for some time.

Are cannabis topicals effective for arthritis pain?

The preclinical evidence is encouraging but limited. A 2016 study by Hammell and colleagues in the European Journal of Pain found that topical CBD reduced joint swelling and pain behaviors in a rat model of arthritis, with decreased inflammatory markers at the application site. CB2 receptors are present in skin and joint tissue, and their activation has documented anti-inflammatory effects. However, human clinical data on topical cannabis for arthritis is sparse, and the placebo response for topically applied pain products is notoriously high. The formulation quality of the topical matters significantly — poorly formulated products may deposit cannabinoids on the skin surface without meaningful penetration to the target tissue.

What is the difference between a topical and a transdermal cannabis product?

The critical difference is penetration depth. Standard topicals (creams, balms, salves) deliver cannabinoids into the skin but not through the skin into the bloodstream. They interact with local CB1 and CB2 receptors in the skin and subcutaneous tissue, producing only localized effects with no psychoactive high and no drug test risk. Transdermal products (patches, some specially formulated gels) are designed to push cannabinoids through all skin layers into the capillary network and systemic circulation. They produce whole-body effects, can cause psychoactive responses (if THC-containing), and will show up on drug tests. The packaging should indicate whether a product is topical-only or transdermal.